MedPath

Post Market Study for an Adhesion Barrier Following Laparoscopic Myomectomy

Not Applicable
Completed
Conditions
Fibroid
Myoma
Leiomyoma
Interventions
Device: SprayShield™
Registration Number
NCT00891657
Lead Sponsor
Integra LifeSciences Corporation
Brief Summary

This study is planned as a prospective, randomised, parallel, controlled, multi-centre, open label, comparative evaluation of SprayShield™ Adhesion Barrier plus good surgical technique, versus good surgical technique alone, with a blinded, third party video evaluation of adhesion formation at second look laparoscopy (SLL) following laparoscopic myomectomy.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
15
Inclusion Criteria
  • Females, 18 years of age or older, of child-bearing potential.
  • Subject has at least one myoma >= 3 cm.
Exclusion Criteria
  • Pregnant or lactating females.
  • Females undergoing prior open or closed myomectomy for treatment of myomas.
  • Evidence of current active endometriosis or infection
  • History of or active inflammatory bowel disease or pelvic inflammatory disease.
  • Presence of a frozen pelvis, or hydrosalpinges.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
SprayShield™SprayShield™SprayShield™
Primary Outcome Measures
NameTimeMethod
Number of Sites Adherent to the Uterus8-12 weeks post myomectomy

The number of times an adhesion is attached to the uterus.

Area of Sites Adherent to the Uterus (cm^2)8-12 weeks post myomectomy
Mean Severity Score of Sites Adherent to the Uterus8-12 weeks post myomectomy

The scoring for severity is as follows: 0=no adhesions, 1=filmy, avascular adhesions, 2=vascular and/or dense adhesions, and 3=cohesive adhesions.

Mean Extent Score of Sites Adherent to the Uterus8-12 weeks post myomectomy

0 =no adhesions, 1=covering \<25% of locations' total area, 2=covering 26% to 50% of locations' total area, and 3=covering \>51% of locations' total area.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Pius Clinic

🇩🇪

Oldenburg, Germany

© Copyright 2025. All Rights Reserved by MedPath